Literature DB >> 8342994

Increased bile duct complications in liver transplantation across the ABO barrier.

L Sanchez-Urdazpal1, K P Batts, G J Gores, S B Moore, S Sterioff, R H Wiesner, R A Krom.   

Abstract

OBJECTIVE: This study evaluated the outcome of liver grafts from ABO incompatible donors, focusing on biliary complications, and compared the results to an ABO compatible control group. Also, the expression of donor ABH antigens in the liver graft was analyzed. SUMMARY BACKGROUND DATA: The outcome of liver transplantation using an ABO incompatible graft is still debated. These blood group related (ABH) antigens are known to be expressed not only on the surface of the erythrocytes, but also on the epithelial cells of large bile ducts. Because the biliary epithelium of hepatic allografts may continue to express donor ABH antigens, it may be more susceptible to immunologic bile duct injury after transplantation across the ABO barrier.
METHODS: Eighteen ABO incompatible grafts were compared with 18 ABO compatible grafts in patients who were matched according to medical urgency, primary liver disease (PLD), and recipient age. After transplantation, the grafts were analyzed with cholangiography, Doppler ultrasound, or arteriography and liver histology according to protocol. Immunoperoxidase staining for ABH antigens was performed on hepatic tissue.
RESULTS: Biliary complications developed in 82% of the ABO incompatible donors, compared to 6% of the ABO matched controls. Hepatic artery thrombosis occurred in 24%. Cellular rejection was diagnosed in 65% versus only 28% in the control group. The 1-year actuarial graft survival rate was 44% versus 78% in the control group. ABH antigens of the donor were expressed on vascular endothelium and bile duct epithelial cells as long as 150 days after transplant.
CONCLUSIONS: Using ABO incompatible allografts, a high incidence of biliary and hepatic artery complications and decreased graft survival in liver transplantation were found. An immunologic injury to the bile duct epithelium and/or to vascular endothelium is suspected.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8342994      PMCID: PMC1242924          DOI: 10.1097/00000658-199308000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  18 in total

1.  Blood group antigens in the intrahepatic biliary tree. I. Distribution in the normal liver.

Authors:  Y Okada; K Jinno; S Moriwaki; T Shimoe; T Tsuji; M Murakami; J Thurin; H Koprowski
Journal:  J Hepatol       Date:  1988-02       Impact factor: 25.083

2.  Present experiences in a series of 26 ABO-incompatible living donor renal allografts.

Authors:  G P Alexandre; J P Squifflet; M De Bruyère; D Latinne; R Reding; P Gianello; M Carlier; Y Pirson
Journal:  Transplant Proc       Date:  1987-12       Impact factor: 1.066

3.  Activity of the ABO antigen system as a determinant of histocompatibility in human transplantation.

Authors:  F T Rapaport; J Dausset
Journal:  Transplant Proc       Date:  1987-12       Impact factor: 1.066

Review 4.  Evolution of liver transplantation.

Authors:  T E Starzl; S Iwatsuki; D H Van Thiel; J C Gartner; B J Zitelli; J J Malatack; R R Schade; B W Shaw; T R Hakala; J T Rosenthal; K A Porter
Journal:  Hepatology       Date:  1982 Sep-Oct       Impact factor: 17.425

5.  Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers.

Authors:  A J Demetris; R Jaffe; A Tzakis; G Ramsey; S Todo; S Belle; C Esquivel; R Shapiro; B Markus; E Mroczek
Journal:  Am J Pathol       Date:  1988-09       Impact factor: 4.307

6.  Liver transplantation across ABO blood groups.

Authors:  R D Gordon; S Iwatsuki; C O Esquivel; A Tzakis; S Todo; T E Starzl
Journal:  Surgery       Date:  1986-08       Impact factor: 3.982

7.  The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation.

Authors:  J Ludwig; R H Wiesner; K P Batts; J D Perkins; R A Krom
Journal:  Hepatology       Date:  1987 May-Jun       Impact factor: 17.425

8.  Monoclonal antibody localization of A and B isoantigens in normal and malignant fixed human tissues.

Authors:  C Ernst; J Thurin; B Atkinson; H Wurzel; M Herlyn; N Stromberg; C Civin; H Koprowski
Journal:  Am J Pathol       Date:  1984-12       Impact factor: 4.307

9.  Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test.

Authors:  T C Fuller; D Phelan; H M Gebel; G E Rodey
Journal:  Transplantation       Date:  1982-07       Impact factor: 4.939

10.  The first 100 liver transplantations at the Mayo Clinic.

Authors:  R A Krom; R H Wiesner; S R Rettke; J Ludwig; P A Southorn; P E Hermans; H F Taswell
Journal:  Mayo Clin Proc       Date:  1989-01       Impact factor: 7.616

View more
  30 in total

1.  Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts.

Authors:  S Takaya; A Jain; A Yagihashi; K Nakamura; M Kobayashi; K Takeuchi; S Suzuki; Y Iwaki; A J Demetris; S Todo; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1999-08       Impact factor: 1.066

2.  Management of biliary complications after orthotopic liver transplantation: the role of endoscopy.

Authors:  Maria-C Londoño; Domingo Balderramo; Andrés Cárdenas
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

3.  Interventional radiology: management of biliary complications of liver transplantation.

Authors:  Nishita Kothary; Aalpen A Patel; Richard D Shlansky-Goldberg
Journal:  Semin Intervent Radiol       Date:  2004-12       Impact factor: 1.513

Review 4.  Endoscopic diagnosis and management of biliary complications following orthotopic liver transplantation.

Authors:  C F Gholson; G Zibari; J C McDonald
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

5.  ABO-Incompatible Living Donor Liver Transplantation in Focus of Antibody Rebound.

Authors:  Silke Rummler; Astrid Bauschke; Erik Baerthel; Heike Juette; Katrin Maier; Christina Malessa; Dagmar Barz; Utz Settmacher
Journal:  Transfus Med Hemother       Date:  2016-11-09       Impact factor: 3.747

6.  Lessons learnt from living donor liver transplantation with ABO-incompatibility: A single-centre experience from southern India.

Authors:  Surumi Shajahan; Sreedurga Thottanchery Sasidharan; Sudhindran Surendran; Veena Shenoy; Uma Devi Padma
Journal:  Indian J Gastroenterol       Date:  2019-03-08

7.  Computed tomography findings in ABO-incompatible living donor liver transplantation recipients with biliary strictures.

Authors:  Sang Hyun Choi; Kyoung Won Kim; So Yeon Kim; Jin Sil Kim; Jae Hyun Kwon; Gi-Won Song; Sung-Gyu Lee
Journal:  Eur Radiol       Date:  2018-01-02       Impact factor: 5.315

8.  Risk factor for ischemic-type biliary lesion after ABO-incompatible living donor liver transplantation.

Authors:  Jun Bae Bang; Bong-Wan Kim; Young Bae Kim; Hee-Jung Wang; Hyun Yeong Lee; Joohyun Sim; Taegyu Kim; Kyeong Lok Lee; Xu-Guang Hu; Wei Mao
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

9.  Adult Living Donor Liver Transplantation with ABO-Incompatible Grafts: A German Single Center Experience.

Authors:  Armin D Goralczyk; Aiman Obed; Andreas Schnitzbauer; Axel Doenecke; Tung Yu Tsui; Marcus N Scherer; Giuliano Ramadori; Thomas Lorf
Journal:  J Transplant       Date:  2010-02-03

Review 10.  Secondary sclerosing cholangitis.

Authors:  Petra Ruemmele; Ferdinand Hofstaedter; Cornelia M Gelbmann
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-05       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.